BRAF mutations are associated with poor prognosis in metastatic colorectal cancer [42], but treatment with drugs such as vemurafenib, which targets BRAF mutations, has demonstrated high efficacy in melanoma patients [43]. This evidence concerns the gene BRAF and metastatic colorectal cancer.